Are Trial Sponsors Treading On Investigators’ Toes In Decentralized Trials?
Executive Summary
The Danish regulator’s experience with reviewing and inspecting decentralized elements in clinical trials highlights concerns around the blurring of lines that divide the roles and responsibilities of sponsors and trial investigators.
You may also be interested in...
UK MHRA Inspector Highlights Mistakes Made In Decentralized Clinical Trials
Inadequate risk assessments, participant confidentiality breaches and issues with documenting and verifying clinical trial activities have emerged as recurring themes in inspections of decentralized clinical trials by the UK medicines regulator.
Decentralized Trial Technologies An ‘Encumbrance’ For Site Personnel, US Survey Shows
The Association of Clinical Research Professionals says the perspective of personnel working at clinical research sites must be taken into account to ensure the effective implementation of decentralized clinical trials.
EU Guidance To Tackle Sponsor/Investigator Overlap In Decentralized Trials
With sponsors of decentralized clinical trials increasingly getting involved in contracting third-party vendors to deliver services that are traditionally overseen by investigators, a much-awaited EU recommendation paper will explain how both parties can maintain control over their distinctive roles.